Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE.
We have previously reported that adenoviral-mediated delivery of cytochrome P-450 (CYP) 4A2, which catalyzes the synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE), results in endothelial dysfunction and hypertension in Sprague-Dawley (SD) rats (Wang JS, Singh H, Zhang F, Ishizuka T, Deng H, Kemp R, Wolin MS, Hintze TH, Abraham NG, Nasjletti A, Laniado-Schwartzman M. Circ Res 98: 962-969, 2006). In this study, we targeted the vascular endothelium by using a lentivirus construct expressing CYP4A2 under the control of the endothelium-specific promoter VE-cadherin (VECAD-4A2) and examined the effect of long-term CYP4A2 overexpression on blood pressure and kidney function in SD rats. A bolus injection of VECAD-4A2 increased blood pressure (P < 0.001) by 26, 36, and 30 mmHg 10, 20, and 30 days postinjection, respectively. Arteries from VECAD-4A2-transduced rats produced increased levels of 20-HETE (P < 0.01), expressed lower levels of endothelial nitric oxide synthase (eNOS) and phosphorylated eNOS (p-eNOS) (P < 0.05), generated higher levels of superoxide anion, and displayed decreased relaxing responsiveness to acetylcholine (P < 0.05). Proteinuria increased by twofold in VECAD-4A2-transduced rats compared with controls. Treatment of VECAD-4A2-transduced rats with HET0016, an inhibitor of 20-HETE biosynthesis, not only attenuated the increase in blood pressure (P < 0.05) but also improved vascular function (acetylcholine-induced relaxations) and reduced plasma creatinine and proteinuria. HET0016 treatment decreased oxidative stress and increased the phosphorylated state of key proteins that regulate endothelial function, including eNOS, AKT, and AMPK. Collectively, these findings demonstrate that augmentation of vascular endothelial 20-HETE levels results in hypertension, endothelial dysfunction, and renal injury, which is offset by HET0016 through a reduction in vascular 20-HETE coupled with a lessening of oxidative stress and the amplification of pAKT, pAMPK, and p-eNOS levels leading to normalization of endothelial responses.
Inoue
Kazuyoshi
K
Dept. of Pharmacology, New York Medical College, Valhalla, NY, USA.
Sodhi
Komal
K
Puri
Nitin
N
Gotlinger
Katherine H
KH
Cao
Jiang
J
Rezzani
Rita
R
Falck
John R
JR
Abraham
Nader G
NG
Laniado-Schwartzman
Michal
M
D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000109:Acetylcholine; D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D001794:Blood Pressure; D015820:Cadherins / Q000235:genetics; D002460:Cell Line; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D018076:DNA, Complementary; D004730:Endothelium, Vascular / Q000378:metabolism*; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis*; D006973:Hypertension / Q000378:metabolism*; D016086:Lentivirus; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010084:Oxidation-Reduction; D010766:Phosphorylation; D011401:Promoter Regions, Genetic; D011507:Proteinuria / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013481:Superoxides / Q000378:metabolism; D014664:Vasodilation; D000099152:Cadherin 5
D055372:AMP-Activated Protein Kinases; D000109:Acetylcholine; D015703:Antigens, CD; D015820:Cadherins; D003577:Cytochrome P-450 Enzyme System; D018076:DNA, Complementary; D006893:Hydroxyeicosatetraenoic Acids; D052250:Nitric Oxide Synthase Type III; D051057:Proto-Oncogene Proteins c-akt; D013481:Superoxides; D000099152:Cadherin 5; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid; C465388:cytochrome P-450 CYP4A2 (rat)
Science. 1991 Feb 15;251(4995):799-802
1846705
Am J Physiol Renal Physiol. 2007 Aug;293(2):F501-5
17507602
Hypertension. 2005 Apr;45(4):643-8
15723968
Science. 1989 Jan 20;243(4889):388-90
2492116
Shock. 2008 Sep;30(3):329-35
18323740
Am J Physiol. 1998 Aug;275(2):R426-38
9688677
Antioxid Redox Signal. 2007 Dec;9(12):2065-74
17883332
J Pharmacol Exp Ther. 2008 Jan;324(1):103-10
17947496
J Appl Physiol (1985). 2002 Jul;93(1):330-7
12070222
Kidney Int. 2007 Jun;71(11):1105-15
17361113
Kidney Int. 2009 Mar;75(5):511-7
19052533
Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2455-65
18952718
Hypertension. 1996 Mar;27(3 Pt 2):564-8
8613204
Am J Physiol Renal Physiol. 2008 Dec;295(6):F1764-77
18842817
Blood. 1999 Jan 1;93(1):184-92
9864160
J Cell Biol. 1992 Sep;118(6):1511-22
1522121
Am J Physiol Regul Integr Comp Physiol. 2002 Jul;283(1):R60-8
12069931
Hypertension. 2000 Oct;36(4):604-9
11040243
J Pharmacol Exp Ther. 2007 Apr;321(1):18-27
17210799
Circulation. 2003 Feb 4;107(4):574-8
12566369
J Am Soc Nephrol. 2008 Apr;19(4):714-21
18235092
Am J Physiol. 1994 Jun;266(6 Pt 1):C1775-82
8023907
Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H1018-26
18156192
Am J Physiol Renal Physiol. 2003 Jan;284(1):F51-6
12388396
Pharmacol Rep. 2008 Jan-Feb;60(1):29-37
18276983
Circ Res. 1998 Nov 30;83(11):1069-79
9831701
Hypertension. 2007 Jul;50(1):123-9
17548721
Hypertension. 2008 May;51(5):1393-8
18391101
Hypertension. 2008 Mar;51(3):767-72
18227405
Am J Physiol Regul Integr Comp Physiol. 2003 Apr;284(4):R1055-62
12531784
Am J Physiol Heart Circ Physiol. 2000 May;278(5):H1517-26
10775129
Br J Pharmacol. 2001 Jun;133(3):325-9
11375247
Hypertension. 2000 Jan;35(1 Pt 2):457-63
10642341
Am J Physiol. 1997 Jul;273(1 Pt 2):R293-300
9249563
Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R255-61
11124159
J Clin Invest. 1997 Nov 1;100(9):2153-7
9410891
Circ Res. 1993 Jan;72(1):126-36
8417836
J Clin Invest. 1997 Mar 15;99(6):1224-30
9077530
Circ Res. 2006 Apr 14;98(7):962-9
16543501
Circ Res. 1991 Apr;68(4):1154-63
1901255
Am J Physiol. 1999 Oct;277(4):H1546-52
10516194
Am J Physiol. 1996 Jan;270(1 Pt 2):R228-37
8769806
Circulation. 2004 Jul 27;110(4):438-43
15262846
J Pharmacol Exp Ther. 1998 Mar;284(3):966-73
9495856
Hypertension. 1993 Jun;21(6 Pt 2):985-8
8505111
Hypertension. 2004 Apr;43(4):860-5
14967839
Kidney Int. 2009 Jun;75(12):1288-1296
19279555
J Biol Chem. 2007 Jul 13;282(28):20351-64
17519230
Hypertension. 2001 Dec 1;38(6):1311-5
11751709
Am J Physiol Renal Physiol. 2002 Jul;283(1):F60-7
12060587
Circ Res. 1996 Jul;79(1):54-61
8925569
Am J Physiol Regul Integr Comp Physiol. 2002 Sep;283(3):R710-20
12185006
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5211-6
11320253
J Pharmacol Exp Ther. 1989 Jan;248(1):229-32
2492340
Curr Drug Metab. 2004 Jun;5(3):245-56
15180494
Exp Physiol. 2005 Sep;90(5):783-90
16049057
Am J Physiol. 1999 Feb;276(2):F246-53
9950955
Am J Hypertens. 2001 Jun;14(6 Pt 2):90S-97S
11411771
Free Radic Biol Med. 2005 Apr 15;38(8):1032-6
15780761
Hypertension. 1993 Sep;22(3):357-64
8349328